United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - pitavastatin calcium (unii: iyd54xeg3w) (pitavastatin - unii:m5681q5f9p) - pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (ldl-c) in: pitavastatin tablets are contraindicated in the following conditions: discontinue pitavastatin tablets when pregnancy is recognized. alternatively, consider the ongoing therapeutic needs of the individual patient. pitavastatin tablets decrease synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, pitavastatin tablets may cause fetal harm when administered to pregnant patients based on the mechanism of action [see clinical pharmacology (12.1)] . in addition, treatment of hyperlipidemia is not generally necessary during pregnancy. atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients. available data from case series and prospective and retrospective observational cohort studies over decades

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - pitavastatin calcium (unii: iyd54xeg3w) (pitavastatin - unii:m5681q5f9p) - pitavastatin is indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (ldl-c) in: - adults with primary hyperlipidemia. - adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (hefh). pitavastatin is contraindicated in the following conditions: - concomitant use of cyclosporine [see drug interactions (7)]. - acute liver failure or decompensated cirrhosis [see warnings and precautions (5.3)]. - hypersensitivity to pitavastatin or any excipents in pitavastatin. hypersensitivity reactions including angioedema, rash, pruritus, and urticaria have been reported with pitavastatin [see adverse reactions (6)]. risk summary discontinue pitavastatin when pregnancy is recognized. alternatively, consider the ongoing therapeutic needs of the individual patient. pitavastatin decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, pitavastatin may cause fetal harm when administered to pregn

United States - English - NLM (National Library of Medicine)

quinn pharmaceuticals, llc - pitavastatin calcium (unii: iyd54xeg3w) (pitavastatin - unii:m5681q5f9p) - drug therapy should be one component of multiple-risk-factor intervention in individuals who require modifications of their lipid profile. lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol only when the response to diet and other nonpharmacological measures has been inadequate. pitavastatin tablets is indicated as an adjunctive therapy to diet to reduce elevated total cholesterol (tc), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia. doses of pitavastatin tablets greater than 4 mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies. do not exceed 4 mg once daily dosing of pitavastatin tablets. the effect of pitavastatin tablets on cardiovascular morbidity and mortality has not been determined. pitavastatin tablets has not been studied in fredrickson type i, iii, and v dyslipid

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals, inc. - pitavastatin calcium (unii: iyd54xeg3w) (pitavastatin - unii:m5681q5f9p) - pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (ldl-c) in: - adult with primary hyperlipidemia. - adults with heterozygous familial hypercholesterolemia (hefh). pediatric use information is approved for kowa co ltd’s livalo (pitavastatin) tablets. however, due to kowa co ltd’s marketing exclusivity rights, this drug product is not labeled with that information. pitavastatin tablets are contraindicated in the following conditions: - concomitant use of cyclosporine [see drug interactions ( 7)] . - acute liver failure or decompensated cirrhosis [see warning and precautions ( 5.3)]. - hypersensitivity to pitavastatin or any excipients in pitavastatin tablets. hypersensitivity reactions including angioedema, rash, pruritus, and urticaria have been reported with pitavastatin tablets [see adverse reactions ( 6)] . risk summary discontinue pitavastatin tablets when pregnancy is recognized. alternatively, consider the ongoing therapeutic needs of the individual patient. pitavastatin tablets decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, pitavastatin may cause fetal harm when administered to pregnant patients based on the mechanism of action [see clinical pharmacology ( 12.1)]. in addition, treatment of hyperlipidemia is not generally necessary during pregnancy. atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients. available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations. published data from prospective and retrospective observational cohort studies with statin use in pregnant women are insufficient to determine if there is a drug associated risk of miscarriage [see data]. in animal reproduction studies, no embryo-fetal toxicity or congenital malformations were observed in pregnant rats and rabbits orally administered pitavastatin during the period of organogenesis at doses which were 22 and 4 times, respectively, the human exposure at the maximum recommended human dosage (mrhd) of 4 mg, based on auc [see data]. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. data human data a medicaid cohort linkage study of 1152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders – including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use – using propensity score-based methods. the relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. there were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders. in the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births. animal data embryo-fetal developmental studies were conducted in pregnant rats administered 3, 10, 30 mg/kg/day pitavastatin by oral gavage during organogenesis (gestation days 7-17). no adverse effects were observed at 3 mg/kg/day, systemic exposures 22 times human systemic exposure at 4 mg/day based on auc. embryo-fetal developmental studies were conducted in pregnant rabbits administered 0.1, 0.3, 1 mg/kg/day pitavastatin by oral gavage during the period of fetal organogenesis(gestation days 6-18). maternal toxicity consisting of reduced body weight and abortion was observed at all doses tested (4 times human systemic exposure at 4 mg/day based on auc). in perinatal/postnatal studies in pregnant rats given oral gavage doses of pitavastatin at 0.1, 0.3, 1, 3, 10, 30 mg/kg/day from organogenesis through weaning (gestation day 17 to lactation day 21), maternal toxicity consisting of mortality at ≥0.3 mg/kg/day and impaired lactation at all doses contributed to the decreased survival of neonates in all dose groups (0.1 mg/kg/day represents approximately 1 time human systemic exposure at 4 mg/day dose based on auc). reproductive toxicity studies have shown that pitavastatin crosses the placenta in rats and is found in fetal tissues at ≤36% of maternal plasma concentrations following a single dose of 1 mg/kg/day during gestation (at the end of organogenesis). risk summary there is no available information about the presence of pitavastatin in human or animal milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production. however, it has been shown that another drug in this class passes into human milk.statins, including pitavastatin tablets, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol and may cause harm to the breastfed infant. because of the potential for serious adverse reactions in a breastfed infant, based upon the mechanism of action, advise patients that breastfeeding is not recommended during treatment with pitavastatin tablets. [see use in specific populations ( 8.1), clinical pharmacology ( 12.1)] the safety and effectiveness of pitavastatin tablets have not been established in pediatric patients younger than 8 years of age with hefh or in pediatric patients with other types of hyperlipidemia (other than hefh). pediatric use information is approved for kowa co ltd’s livalo (pitavastatin) tablets. however, due to kowa co ltd’s marketing exclusivity rights, this drug product is not labeled with that information. in controlled clinical studies, 1,209 (43%) patients were 65 years and older. no significant differences in efficacy or safety were observed between geriatric patients and younger patients. advanced age (≥65 years) is a risk factor for pitavastatin tablets-associated myopathy and rhabdomyolysis. dose selection for a geriatric patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. monitor geriatric patients receiving pitavastatin tablets for the increased risk of myopathy [see warnings and precautions ( 5.1)]. renal impairment is a risk factor for myopathy and rhabdomyolysis. monitor all patients with renal impairment for development of myopathy. due to the risk of myopathy, a dosage modification of pitavastatin tablets is recommended for patients with moderate and severe renal impairment (estimated glomerular filtration rate 30 – 59 ml/min/1.73 m 2 and 15 – 29 ml/min/1.73 m 2 , respectively), as well as end-stage renal disease receiving hemodialysis. [see dosage and administration ( 2.3), warnings and precautions ( 5.1), clinical pharmacology ( 12.3)]. pitavastatin is contraindicated in patients with active liver failure or decompensated cirrhosis [see contraindications ( 4), warnings and precautions ( 5.3)].

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - pitavastatin calcium (unii: iyd54xeg3w) (pitavastatin - unii:m5681q5f9p) -

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - pitavastatin calcium (unii: iyd54xeg3w) (pitavastatin - unii:m5681q5f9p) - pitavastatin tablets are  indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (ldl-c) in: - adults with primary hyperlipidemia. - adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (hefh). pitavastatin tablets are contraindicated in the following conditions: - concomitant use of cyclosporine [see drug interactions (7)]. - acute liver failure or decompensated cirrhosis  [see warnings and precautions (5.3)] . - hypersensitivity to pitavastatin or any excipents in pitavastatin tablets. hypersensitivity reactions including angioedema, rash, pruritus, and urticaria have been reported with pitavastatin tablets [see adverse reactions (6.1)]. risk summary discontinue pitavastatin when pregnancy is recognized. alternatively, consider the ongoing therapeutic needs of the individual patient. pitavastatin decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, pitavastatin may cause fetal harm when administered to pregnant patients based on the mechanism of action [see clinical pharmacology (12.1)]. in addition, treatment of hyperlipidemia is not generally necessary during pregnancy. atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients. available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations. published data from prospective and retrospective observational cohort studies with statin use in pregnant women are insufficient to determine if there is a drug associated risk of miscarriage (see data) . in animal reproduction studies, no embryo-fetal toxicity or congenital malformations were observed in pregnant rats and rabbits orally administered pitavastatin during the period of organogenesis at doses which were 22 and 4 times, respectively, the human exposure at the maximum recommended human dosage (mrhd) of 4 mg, based on auc [see data]. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data human data a medicaid cohort linkage study of 1152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders - including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use - using propensity score-based methods. the relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. there were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders. in the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births. animal data embryo-fetal developmental studies were conducted in pregnant rats administered 3, 10, 30 mg/kg/day pitavastatin by oral gavage during organogenesis (gestation days 7 to 17).  no adverse effects were observed at 3 mg/kg/day, systemic exposures 22 times human systemic exposure at 4 mg/day based on auc. embryo-fetal developmental studies were conducted in pregnant rabbits administered 0.1, 0.3, 1 mg/kg/day pitavastatin by oral gavage during the period of fetal organogenesis (gestation days 6 to 18). maternal toxicity consisting of reduced body weight and abortion was observed at all doses tested (4 times human systemic exposure at 4 mg/day based on auc). in perinatal/postnatal studies in pregnant rats given oral gavage doses of pitavastatin at 0.1, 0.3, 1, 3, 10, 30 mg/kg/day from organogenesis through weaning (gestation day 17 to lactation day 21), maternal toxicity consisting of mortality at ≥0.3 mg/kg/day and impaired lactation at all doses contributed to the decreased survival of neonates in all dose groups (0.1 mg/kg/day represents approximately 1 time human systemic exposure at 4 mg/day dose based on auc). reproductive toxicity studies have shown that pitavastatin crosses the placenta in rats and is found in fetal tissues at ≤36% of maternal plasma concentrations following a single dose of 1 mg/kg/day during gestation (at the end of organogenesis). risk summary there is no available information about the prescence of pitavastatin in human or animal milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. however, it has been shown that another drug in this class passes into human milk. statins, including pitavastatin, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol and may cause harm to the breastfed infant. because of the potential for serious adverse reactions in a breastfed infant, based upon the mechanism of action, advise patients that breastfeeding is not recommended during treatment with pitavastatin. [see use in specific populations (8.1), clinical pharmacology (12.1)] the safety and effectiveness of pitavastatin as an adjunctive therapy to diet to reduce elevated ldl-c in pediatric patients aged 8 years and older with hefh have been established. use of pitavastatin for this indication is supported by a 12-week, double-blind, placebo-controlled trial in 82 pediatric patients 8 to 16 years of age with hefh [see clinical studies (14.2)] and a 52-week open-label trial in 85 pediatric patients with hefh. the safety and effectiveness of pitavastatin have not been established in pediatric patients younger than 8 years of age with heterozygous familial hypercholesterolemia (hefh) or in pediatric patients with other types of hyperlipidemia (other than hefh). in controlled clinical studies, 1,209 (43%) patients were 65 years and older. no overall differences in safety or effectiveness were observed between these patients and younger patients. advanced age (≥65 years) is a risk factor for pitavastatin-associated myopathy and rhabdomyolysis. dose selection for a geriatric patient should be cautious, reognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. monitor geriatric patients receiving pitavastatin for the increased risk of myopathy [see warnings and precautions (5.1)]. renal impairment is a risk factor for myopathy and rhabdomyolysis. monitor all patients with renal impairment for development of myopathy. due to the risk of myopathy, a dosage modification of pitavastatin is recommended for patients with moderate and severe renal impairment (estimated glomerular filtration rate 30 to 59 ml/min/1.73 m2 and 15 to 29 ml/min/1.73 m2 , respectively), as well as end-stage renal disease receiving hemodialysis. [see dosage and administration (2.3), warnings and precautions (5.1), clinical pharmacology (12.3)] . pitavastatin is contraindicated in patients with active liver failure or decompensated cirrhosis  [see contraindications (4), warnings and precautions (5.3)] .

United States - English - NLM (National Library of Medicine)

kowa pharmaceuticals america, inc. - pitavastatin calcium (unii: iyd54xeg3w) (pitavastatin - unii:m5681q5f9p) - pitavastatin 1.045 mg - livalo is indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (ldl-c) in: - adults with primary hyperlipidemia. - adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (hefh). livalo is contraindicated in the following conditions: - concomitant use of cyclosporine [see drug interactions (7)]. - acute liver failure or decompensated cirrhosis [see warnings and precautions (5.3)]. - hypersensitivity to pitavastatin or any excipents in livalo. hypersensitivity reactions including angioedema, rash, pruritus, and urticaria have been reported with livalo [see adverse reactions (6)] . risk summary discontinue livalo when pregnancy is recognized. alternatively, consider the ongoing therapeutic needs of the individual patient. livalo decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, livalo may cause fetal harm when administered to pregnant patients based on the mechanism of action [see clinical pharmacology (12.1)]. in addition, treatment of hyperlipidemia is not generally necessary during pregnancy. atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients. available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations. published data from prospective and retrospective observational cohort studies with statin use in pregnant women are insufficient to determine if there is a drug associated risk of miscarriage (see data) . in animal reproduction studies, no embryo-fetal toxicity or congenital malformations were observed in pregnant rats and rabbits orally administered pitavastatin during the period of organogenesis at doses which were 22 and 4 times, respectively, the human exposure at the maximum recommended human dosage (mrhd) of 4 mg, based on auc [see data]. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. data human data a medicaid cohort linkage study of 1152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders – including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use – using propensity score-based methods. the relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. there were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders. in the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births. animal data embryo-fetal developmental studies were conducted in pregnant rats administered 3, 10, 30 mg/kg/day pitavastatin by oral gavage during organogenesis (gestation days 7-17). no adverse effects were observed at 3 mg/kg/day, systemic exposures 22 times human systemic exposure at 4 mg/day based on auc. embryo-fetal developmental studies were conducted in pregnant rabbits administered 0.1, 0.3, 1 mg/kg/day pitavastatin by oral gavage during the period of fetal organogenesis (gestation days 6-18). maternal toxicity consisting of reduced body weight and abortion was observed at all doses tested (4 times human systemic exposure at 4 mg/day based on auc). in perinatal/postnatal studies in pregnant rats given oral gavage doses of pitavastatin at 0.1, 0.3, 1, 3, 10, 30 mg/kg/day from organogenesis through weaning (gestation day 17 to lactation day 21), maternal toxicity consisting of mortality at ≥0.3 mg/kg/day and impaired lactation at all doses contributed to the decreased survival of neonates in all dose groups (0.1 mg/kg/day represents approximately 1 time human systemic exposure at 4 mg/day dose based on auc). reproductive toxicity studies have shown that pitavastatin crosses the placenta in rats and is found in fetal tissues at ≤36% of maternal plasma concentrations following a single dose of 1 mg/kg/day during gestation (at the end of organogenesis). risk summary there is no available information about the prescence of pitavastatin in human or animal milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. however, it has been shown that another drug in this class passes into human milk. statins, including livalo, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol and may cause harm to the breastfed infant. because of the potential for serious adverse reactions in a breastfed infant, based upon the mechanism of action, advise patients that breastfeeding is not recommended during treatment with livalo. [see use in specific populations (8.1), clinical pharmacology (12.1)] the safety and effectiveness of livalo as an adjunctive therapy to diet to reduce elevated ldl-c in pediatric patients aged 8 years and older with hefh have been established. use of livalo for this indication is supported by a 12-week, double-blind, placebo-controlled trial in 82 pediatric patients 8 to 16 years of age with hefh [see clinical studies (14.2)] and a 52-week open-label trial in 85 pediatric patients with hefh. the safety and effectiveness of livalo have not been established in pediatric patients younger than 8 years of age with hefh or in pediatric patients with other types of hyperlipidemia (other than hefh). in controlled clinical studies, 1,209 (43%) patients were 65 years and older. no overall differences in safety or effectiveness were observed between these patients and younger patients. advanced age (≥65 years) is a risk factor for livalo-associated myopathy and rhabdomyolysis. dose selection for a geriatric patient should be cautious, reognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. monitor geriatric patients receiving livalo for the increased risk of myopathy [see warnings and precautions (5.1)]. renal impairment is a risk factor for myopathy and rhabdomyolysis. monitor all patients with renal impairment for development of myopathy. due to the risk of myopathy, a dosage modification of livalo is recommended for patients with moderate and severe renal impairment (estimated glomerular filtration rate 30 – 59 ml/min/1.73 m2 and 15 – 29 ml/min/1.73 m2 , respectively), as well as end-stage renal disease receiving hemodialysis. [see dosage and administration (2.3), warnings and precautions (5.1), clinical pharmacology (12.3)] . livalo is contraindicated in patients with active liver failure or decompensated cirrhosis [see contraindications (4), warnings and precautions (5.3)] .

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

towa pharmaceutical co., ltd. - pitavastatin calcium hydrate - white tablet with split line, diameter: 6.1mm, thickness: 2.9mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

zensei pharmaceutical industries co., ltd. - pitavastatin calcium hydrate - white tablet, diameter: 6.1 mm, thickness: 2.7 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

zensei pharmaceutical industries co., ltd. - pitavastatin calcium hydrate - very light yellowish red tablet, diameter: 7.1 mm, thickness: 3.0 mm